Kestra Medical Technologies (NASDAQ:KMTS) Now Covered by Wolfe Research

Wolfe Research initiated coverage on shares of Kestra Medical Technologies (NASDAQ:KMTS) in a research note issued to investors on Monday morning, Marketbeat reports. The firm issued an outperform rating and a $29.00 target price on the stock.

KMTS has been the subject of several other reports. Stifel Nicolaus started coverage on Kestra Medical Technologies in a research report on Monday. They issued a “buy” rating and a $28.00 price target for the company. The Goldman Sachs Group began coverage on Kestra Medical Technologies in a research note on Monday. They issued a “neutral” rating and a $24.00 target price for the company. Wells Fargo & Company initiated coverage on Kestra Medical Technologies in a research report on Monday. They set an “overweight” rating and a $28.00 price target on the stock. Finally, Piper Sandler assumed coverage on shares of Kestra Medical Technologies in a research note on Monday. They set an “overweight” rating and a $27.00 price objective for the company. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.67.

Kestra Medical Technologies Trading Up 6.4 %

KMTS opened at $24.92 on Monday. Kestra Medical Technologies has a 12 month low of $20.00 and a 12 month high of $25.98.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.